health_en

Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countries. This is the fifth major breast cancer medication introduced by Kexing Biopharm, which further enriches its product portfolio for breast cancer treatment. […]

thaipr.net

8 ม.ค. 67

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with clinical stage generative artificial intelligence (AI)-driven biotechnology company Insilico Medicine (“Insilico”), today announced…

thaipr.net

5 ม.ค. 67

Therabody, the Global Leader In Wellness Technology, Defends Against Recent Patent Infringement Lawsuit Filed by Hyperice

As the leading percussive patent owner and the driving force behind many of today’s wellness innovations, Therabody will vigorously defend itself against the recent patent infringement lawsuit filed by Hyperice. Therabody, the leader in tech wellness and percussive massage therapy, announced today that it will be vigorously defending itself in the recent patent infringement lawsuit […]

thaipr.net

5 ม.ค. 67

JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China accepted the supplemental Biological License Application (sBLA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product Carteyva® (relmacabtagene autoleucel injection)…

thaipr.net

5 ม.ค. 67

Cutting-Edge Gut Microbiome Research: NOSTER’s latest solutions for comprehensive gut bacteria-based metabolite and microbiota analysis

Japan’s Noster Inc., a premier provider of gut microbiome analysis services, is proud to unveil groundbreaking updates in its research on cutting-edge gut bacteria-based metabolite and gut microbiota analysis services. These advancements have far-reaching implications for research on human health and diseases such as diabetes, dietary supplement development, and innovative functional foods. Noster analytics…

thaipr.net

21 ธ.ค. 66

Burjeel Holdings Oncology Conference Marks 10 Years, Focusing on Equitable Solutions for Cancer Care

Experts stress collaboration and innovation are key to progress The 10th anniversary of the Burjeel Holdings Oncology Conference, held in partnership with Foreign Policy, brought together leading global experts to tackle the complex challenges of cancer care, emphasizing the need for multi-stakeholder collaboration. With cancer claiming millions of lives globally, disproportionately impacting low- and middle-income countries, […]

thaipr.net

20 ธ.ค. 66
1 … 17 18 19 20 21 … 128

Copyright © 2025 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.